In the fast-paced landscape of healthcare, the evaluation and approval of new drugs are a complex and multifaceted endeavour. Regulatory bodies and health technology assessment (HTA) organisations are tasked with …
-
-
In recent years, the field of companion diagnostic (CDx) testing has significantly evolved, becoming a crucial component in the landscape of precision medicine. The increasing reliance on these tests for …
-
In the ever-evolving landscape of healthcare, reimbursement models play a crucial role in shaping the behaviour of healthcare stakeholders and providers. Traditional reimbursement models, such as Fee-for-Service, Reference Pricing, and …
-
News
Dutch Healthcare Institute (ZIN) announces two projects awarded under round 9 of the subsidy scheme for promising care
In April 2024, the Dutch Healthcare Institute (ZIN) announced two projects awarded under round 9 of the subsidy scheme for promising care: Targeted muscle reinnervation during leg amputation in patients …
-
News
Unveiling the Promise and Challenges of AI in Chest X-ray Interpretation for Lung Cancer Detection
In recent years, the integration of artificial intelligence (AI) into healthcare, particularly in radiology, has garnered significant attention. One area where AI shows promising potential is in the interpretation of …
-
The Ministry of the Interior and Health in Denmark is spearheading the establishment of the Board for Health Apps (Nævnet for sundhedsapps), a significant initiative aimed at enhancing the evaluation …
-
In an era marked by technological advancements and the increasing integration of digital solutions into healthcare, understanding the reimbursement landscape for digital health interventions is crucial. Across Europe and Israel, …
-
In a recent report released by NHS England, concerning findings have surfaced regarding the occurrence of ‘never events’ across several hospital trusts in the ITV Tyne Tees region. These serious …
-
News
The Innovative Medicines Fund: a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep?
Given the ever-increasing prices of new drugs,1 the use of health technology assessment (HTA) by healthcare payers and insurers for guiding reimbursement and pricing decisions is becoming increasingly important …
-
The Innovative Medicines Fund (IMF) represents a significant stride in healthcare accessibility, stemming from the triumph of its predecessor, the Cancer Drugs Fund (CDF). Launched in June 2022, the IMF …